Clinical Trials ArenaOriginal article
Can-Fite’s Namodenoson meets primary safety endpoints in Phase IIa trial
Phase 2positiveNamodenosonPositive
AI Analysis
Summary
Can-Fite reported that its Phase IIa study of Namodenoson in advanced pancreatic ductal adenocarcinoma patients met its primary safety endpoint.
Clinical Trial Data
Phase
IIa
Primary Endpoint
Met
Outcome Details
Primary safety endpoint met
Importance:6/10
Sentiment:
0.60
Phase 2safety endpointpancreatic cancerCan-Fite
Read the original article
Published by Clinical Trials Arena on July 2, 2026 7:30 AM